Pishiobury House, Pishiobury Drive
Herts CM Sawbridgeworth
+44 (1477) 539539
Exco InTouch Joins Critical Path Institute ePRO Consortium to Advance Electronic Data Capture in Clinical Trials
The ePRO Consortium is committed to improving the quality, practicality and acceptability of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment. As PRO endpoints have become increasingly common in studies for evaluating patients' perspectives of a particular drug, the requirement for better measures of patients' experiences has become even more critical. Exco InTouch will work closely with other Consortium members from a number of industry-leading providers of innovative electronic data collection technologies, to develop guidelines for the adaptation of PRO measures to the appropriate ePRO solutions.
The ePRO Consortium will generate measurement equivalence data, develop specification documents and data standards, and produce methodological guidance on measurement issues related to ePRO applications. The association will also work closely with C-Path's PRO Consortium, a group of 25 pharmaceutical companies working to develop novel PRO measures, with the goal of making these new measures available for electronic data capture formats. The aim of the programme is to enhance public health by optimising the value of PRO data in medical product evaluation and clinical decision making.
"Exco InTouch is delighted to join the ePRO Consortium to help advance the science of electronic data capture and create standardised guidelines to ensure all data collated electronically in clinical trials is valid and reliable," comments Tim Davis, CEO of Exco InTouch. "The Consortium provides a neutral and collaborative environment for the industry to work together to develop and advocate consistent approaches for drug development."
About Critical Path Institute (C-Path)
C-Path is an independent non-profit institute created in 2005 by the University of Arizona and the U.S. Food and Drug Administration (FDA). Its neutral status allows C-Path to serve as an effective facilitator among scientists from the government, academia and the private sectors. C-Path has forged key partnerships, created collaborations and helped build new working relationships among federal regulators and the pharmaceutical industry. Led by C-Path, scientists from academia, biotechnology companies, the government and pharmaceutical industry are working together to develop innovative new testing methods that enable life-saving drugs, devices and biological products to reach patients faster and with greater safety.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.